Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • MLASCs
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

COVID-19

Updates

See latest Press Relases
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform

Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform

27 Aug 2026 14 Minutes 0 1410
...
Avatar photo
Celularity Inc.
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

4 Jun 2026 12 Minutes 0 1405
...
Avatar photo
Celularity Inc.
Celularity Releases CEO Letter to Shareholders

Celularity Releases CEO Letter to Shareholders

3 Jun 2026 14 Minutes 0 1400
...
Avatar photo
Celularity Inc.
Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

3 Jun 2026 9 Minutes 0 1409
...
Avatar photo
Celularity Inc.
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

6 May 2026 6 Minutes 0 1400
...
Avatar photo
Celularity Inc.
Load more
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells including CAR-T cells, targeting indications across age-related diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Manufacturing
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • MLASCs
  • Exosomes
  • Lifebank
  • Advanced Biomaterials

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Manufacturing
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • MLASCs
  • Exosomes
  • Lifebank
  • Advanced Biomaterials
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions